Latest: FDA Approves New Biosimilar for Oncology Treatment
Neurology

NaV1.8 Pain Signal Inhibitor VX-993 Fails to Show Efficacy in Phase 2 Trial of Acute Pain

by Neurology Live
0 Comments
0 Mins
Vertex Pharmaceuticals halts VX-993 development for acute pain after phase 2 trial shows no significant efficacy compared with placebo.
Tags:
Neurology Live
Author

Neurology Live

Previous Post
The Echo Chamber of Cardiology: Practicing Medicine—or Managing Metrics?
Next Post
Iovance cuts staff amid slow sales start for ‘TIL’ cell therapy
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago